---
schema_version: "secwatch.filing_event.v1"
accession: "0000896622-25-000031"
form_type: "8-K"
ticker: "ATR"
cik: "0000896622"
company_name: "APTARGROUP, INC."
filed_at: "2025-10-30T23:59:59+00:00"
generated_at: "2026-05-17T01:31:01.218321+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# AptarGroup Q3 2025: adj. EPS $1.62 (+4% YoY); pharma injectables surge 18%; Q4 adj. EPS guidance $1.20-$1.28

## Summary
- Reported sales $961M (+6% YoY); core sales +1%. Reported EPS $1.92 (+30%); adjusted EPS $1.62 (+4%).
- Pharma injectables sales surged 18% driven by GLP-1 components; Pharma core sales +2%.
- Beauty core sales flat; Closures core sales -1% due to lower tooling and resin pass-throughs.
- Q4 adjusted EPS guidance $1.20-$1.28; returned $70M to shareholders in Q3 via repurchases and dividends.

## SEC filing metadata
- accession: 0000896622-25-000031
- form_type: 8-K
- ticker: ATR
- cik: 0000896622
- company_name: APTARGROUP, INC.
- filed_at: 2025-10-30T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/896622/000089662225000031/0000896622-25-000031-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/896622/000089662225000031/atr-20251030.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000896622-25-000031
- JSON: https://secwatch.observer/filing/0000896622-25-000031.json
- Plain text: https://secwatch.observer/filing/0000896622-25-000031.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.